Iterum Therapeutics Reports First Quarter 2019 Financial Results
May 14, 2019 07:00 ET
|
Iterum Therapeutics plc
On track to complete enrollment in all three Phase 3 clinical trials before year-end Filed patent application that may extend Iterum’s intellectual property rights into the 2040s DUBLIN,...
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
April 14, 2019 07:42 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 ...
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
April 11, 2019 07:30 ET
|
Iterum Therapeutics plc
The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen. Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to...
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
April 03, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Data to be Presented in Oral Session at...
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
April 02, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 2 April...
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
March 19, 2019 07:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 19, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
February 13, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show...
Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic
January 03, 2019 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and...
Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights
November 14, 2018 07:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...